The overall survival rate for patients with colorectal cancer (CRC) has been improving due to recent advances in chemotherapy, such as the use of molecular-targeting therapy. However, patients with metastatic CRC still face a dismal prognosis. More than 1 million individuals develop CRC every year and the disease-specific mortality rate is nearly 33% in the developed world due to disease progression ([@bib3]).

In order to improve survival of patients with metastatic CRC, early detection or prediction of metastasis is required. Several biomarkers have been introduced to increase treatment efficacy. The most important development in biomarkers for metastatic CRC has been the validation of *KRAS* mutation status as a predictor of non-responsiveness to epidermal growth factor receptor (EGFR)-targeted therapy ([@bib16]). In the adjuvant setting, prognostic and predictive molecular markers (microsatellite instability and 18q imbalance) could potentially be used to discriminate between molecular phenotypes in stage II disease (clinically heterogeneous), thereby contributing to the risk-benefit assessment of adjuvant treatment ([@bib12]; [@bib31]; [@bib47]; [@bib36]; [@bib37]). However, complex pathways contribute to progression of the disease and, in general, single markers might not be entirely useful for prediction of efficacy and outcome. With high-throughput genome-wide screening, predictive and prognostic molecular signatures are increasingly being sought but, as yet, none have been validated for clinical use.

Recent studies have suggested that the involvement of sialyltransferase and fucosyltransferases (FUTs) on cancer progression such as cancer cell metastasis and invasion are mediated by modification of the cell surface by these enzymes to attachment of glycosyl residues ([@bib32]). For one of the typical examples, it has been shown that silaylation and fucosylation of the EGFR have significant role in regulating its signal ([@bib46]; [@bib25]; [@bib24]).

Among several glycosylation enzymes, we focused on the biological characteristics of metastatic CRC, especially with respect to fucosylated antigens, such as sialyl Lewis x (sLe^X^) and sialyl Lewis a antigen (sLe^a^, CA19-9), which are found in the sera and tumour tissues of CRC patients ([@bib8]; [@bib30]). Fucosylated antigens are used as tumour markers for cancer detection and evaluation of treatment efficacy. For example, CA19-9 is frequently elevated in patients with CRC (∼60%) and has been identified as highly useful tumour marker for the disease ([@bib19]). It has also been shown that elevated CA19-9 levels are associated with a lower postoperative survival rate among CRC patients ([@bib5]; [@bib20]; [@bib34]). Similar to CA19-9, elevation of sLe^x^ expression has also been shown to signify a poor prognosis in patients with CRC ([@bib6]; [@bib29]).

For the synthesis of CA19-9, fucosyltransferase 3 (FUT3) adds L-fucose in an *α*(1,4) linkage to sialylated precursors ([@bib41]; [@bib26]). Conversely, for synthesis of sLe^x^, fucosyltransferase 6 (FUT6) and perhaps FUT3 also add L-fucose in a *α*(1,3) linkage to sialylated precursors ([@bib49]). It has been reported that enhanced activity of FUTs is associated with increased metastatic potential of CRC cells ([@bib10]; [@bib14]; [@bib28]), suggesting that fucosylation and L-fucose may have an important role in disease progression ([@bib8]). In fact, these observations led us to investigate the ability of L-fucose-bound liposomes to target CA19-9-producing pancreatic cancer cells ([@bib50]). Although it has been shown that suppression of FUTs inhibits E-selectin-mediated adhesion to endothelial cells and liver metastasis of a CRC cell line ([@bib48]; [@bib15]), the precise mechanisms underlying the potentiation of cancer cell malignancy by FUTs remain unknown.

Transforming growth factor-*β* (TGF-*β*) is a regulator of cell cycle progression and is considered a critical factor involved in the late stages of tumourigenesis ([@bib22]). Transforming growth factor-*β* is frequently overexpressed in metastatic colon cancer, and circulating levels of this cytokine may be an indicator of liver metastasis ([@bib35]; [@bib42]; [@bib2]). A previous study demonstrated the antimetastatic role of Smad4 in a preclinical model of liver metastasis ([@bib52]). However, the mechanisms by which TGF-*β* promote liver metastasis are unknown.

Transforming growth factor-*β* is a major inducer of epithelial--mesenchymal transition (EMT) in different cell systems, including colon and hepatic cells ([@bib13]; [@bib1]; [@bib7]; [@bib17]). Transforming growth factor-*β*-mediated EMT allows epithelial cells to acquire a fibroblastic morphology, losing their polarity and expression of E-cadherin as well as other cell--cell adhesion molecules, with a concomitant increase in the expression of mesenchymal markers ([@bib43]; [@bib2]). The newly acquired phenotype of tumour cells that have undergone EMT is thought to contribute to tumour cell spread and metastasis.

In this study, we focused on FUTs that were responsible for CA19-9 synthesis and investigated the involvement of signal transduction pathways related to cancer cell metastasis through EMT. Herein, we demonstrated that FUT3 and FUT6 could activate TGF-*β* receptors (T*β*Rs) through fucosylation and enhanced TGF-*β* signalling, resulting in CRC cell migration and invasion possibly through EMT. Thus, these results suggest that FUT3 and FUT6 potentiates cancer cell adhesion to endothelial cells by upregulation of sialyl Lewis antigens and also by enhancement of cancer cell metastasis by EMT through TGF-*β*-mediated EMT.

Materials and methods
=====================

Cell lines
----------

Colo205, Ls174T, HT29 and HCT15 cells were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). Ls180 cells were obtained from Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan). Colo205 and HCT15 were cultured in RPMI 1640 (Life Technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS), L-glutamine and 1% penicillin--streptomycin. Ls174T and Ls180 were cultured in DMEM (Life Technologies) supplemented with 10% FBS, L-glutamine and 1% penicillin--streptomycin. HT29 cells were cultured in McCoy\'s 5 A medium (Life Technologies) supplemented with 10% FBS, L-glutamine and 1% penicillin--streptomycin.

Small interfering RNA and transfection
--------------------------------------

Small interfering RNA oligonucleotides were synthesised in a purified and annealed duplex form. The sequences targeting the human *FUT* gene are as follows: random; sense, 5′-CCUUAUACCUAACGACAGACCCUUU-3′, antisense, 5′-AAAGGGUCUGUCGUUAGGUAUAAGG-3′, FUT3; sense, 5′-CCGCACUGCUAUUUCAGCUGCUGGU-3′, antisense, 5′-ACCAGCAGCUGAAAUAGCAGUGCGG-3′, FUT6; sense, 5′-GCUGUCUGACCACGCUGCUGUUUCA-3′, antisense, 5′-UGAAACAGCAGCGUGGUCAGACAGC-3′. Small interfering RNA transfection experiments were carried out using TransMessenger transfection reagent (Qiagen, Hamburg, Germany) with 100 n[M]{.smallcaps} siRNA according to the manufacturer\'s instructions (Qiagen). Forty hours after siRNA transfection, cells were analysed for *FUT* mRNA expression and used in the experiments described below.

Wound healing assay and cell migration assay
--------------------------------------------

Cells were harvested 48 h after transfection and then wound healing and cell migration assays were conducted using CytoSelect Wound Healing and Cell Migration assay kits (Cell Biolabs Inc., San Diego, CA, USA), respectively, according to the manufacturer\'s instructions. In brief, the wound healing assay was performed using a 24-well plate with CytoSelect Wound Healing Inserts. Cell suspensions containing 5 × 10^5^ cells were added to the wells and incubated overnight. After removing the inserts, the cells were incubated for varying time periods as indicated and the wound healing surface area was calculated. Cell invasion was measured with a CytoSelect Cell Migration assay kit (Cell Biolabs Inc.). Cells were starved overnight in serum-free medium and resuspended at a concentration of 2.5 × 10^5^ cells per ml in serum-free medium containing 0.1% BSA. Cell suspension (0.2 ml) was added to the top of each well, and 10 mg ml^−1^ fibronectin solution was added to the bottom well of the chamber as a chemoattractant. Forty-eight hours later, the cells remaining in the top chamber were carefully removed from the upper surface of the filters using a cotton swab. Cells that migrated to the lower surface of the filter were fixed with methanol and stained with methylene blue. Cell migration was quantitated by counting five random fields per filter at × 40 magnification. Data are presented as the mean number of cells per high-power field based on triplicate measurements from two independent experiments.

Western blotting and immunoprecipitation
----------------------------------------

Cells were solubilised in 1% Triton X-100 lysis buffer (20 m[M]{.smallcaps} Tris-HCl, pH 7.4, 10 m[M]{.smallcaps} EGTA, 10 m[M]{.smallcaps} MgCl~2~, 1 m[M]{.smallcaps} Na~3~VO~4~, 20 m[M]{.smallcaps} NaF, 2 *μ*g ml^−1^ aprotinin, 5 *μ*g ml^−1^ leupeptin and 0.1 m[M]{.smallcaps} phenylmethylsulfonyl fluoride), and then centrifuged at 15 000 *g* for 15 min. The supernatants were collected and protein concentrations were determined using a BCA protein assay kit (Thermo Scientific Inc., Rockford, IL, USA). Equal amounts of protein were run on 4--20% SDS--PAGE under reducing conditions and then transferred to PVDF membranes (Millipore Corp., Billerica, MA, USA). The blots were probed with anti-FUT3, anti-FUT6 antibodies (Abcam, Cambridge, MA, USA), anti-pSmad2, anti-pHSP27, anti-p-p38, anti-Snail, anti-ZEB1 and anti-E-cadherin antibodies (Cell Signaling, Beverly, MA, USA). Immunoreactive bands were visualised using an ECL kit (GE Healthcare Science, Pittsburgh, PA, USA). These membranes were stripped using stripping buffer (Thermo Scientific Inc.) and reprobed with an antibody against the corresponding proteins Smad2, HSP27 and p38 (Cell Signaling) to confirm equal loading. For the immunoprecipitation assay, cell lysates (∼1 mg of protein) prepared as described above, were incubated with anti-T*β*R-I or T*β*R-II antibody (Cell Signaling) overnight at 4 °C with gentle rocking. The immunoprecipitate was washed five times with lysis buffer and lectin blotting was performed as described below. The blots were quantified using LAS-4000UV mini and MultiGauge software (Fujifilm, Tokyo, Japan). Western blotting and immunoprecipitation studies for the indicated antibodies were performed three times to confirm the results.

Lectin blotting analysis
------------------------

Whole*-*cell lysate or immunoprecipitate was subjected to 4--20% SDS--PAGE and transferred to PVDF membranes. The membranes were blocked with 5% BSA in Tris-buffered saline with 0.05% Tween-20 (TBST) overnight at 4 °C and then incubated with 0.5 *μ*g ml^−1^ biotinylated Aleuria aurantia lectin (AAL; J-Oil Mills, Tokyo, Japan), which preferentially recognises Fuc*α*1,3GlcNAc and Fuc*α*1,6GlcNAc, in TBST for 1 h at room temperature. After washing with TBST four times, the membrane was incubated with HRP-conjugated streptavidin for 30 min, and lectin-reactive proteins were then detected using an ECL kit (GE Healthcare Science). The blots were quantified using LAS-4000UV mini and MultiGauge software (Fujifilm). Western blot and immunoprecipitation studies for the indicated antibodies were performed three times for confirmation of results.

Immunofluorescence
------------------

Cells were rinsed twice with PBS, fixed in paraformaldehyde (PFA) 4% for 10 min at RT, dried, washed with PBS and blocked for 1 h in 0.1% BSA in PBS. Filters were then incubated first with Ab (diluted in blocking solution) for 1 h, washed five times in PBS containing 0.05% Tween, treated with similarly prepared dilutions of secondary antibodies for 30 min and washed again as above. Tetramethylrhodamine isothiocyanate-conjugated secondary antibodies against rabbit IgG (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) were diluted 1 : 1000. Confocal analysis was performed using a Leica TCS-NT confocal microscope and the expression level of E-cadherin was quantified by NIH Image.

Statistics
----------

Results are presented as the mean (± s.d.) for each sample. Differences between the two groups were examined by unpaired *t-*test and paired *t-*test. If two groups could not be considered to be of equal variance, *t-*test with Welch\'s correction was performed.

Additional materials and methods are available in [Supplementary Information Online](#sup1){ref-type="supplementary-material"}.

Results
=======

Both FUT3 and FUT6 are essential for activation of Smad signalling upon TGF-*β* stimulation
-------------------------------------------------------------------------------------------

To elucidate the mechanism by which cell growth and invasion is regulated by FUT3 and FUT6, we focused on TGF-*β* signalling, as TGF-*β* has been reported to have an important role in EMT, which triggers cancer cell metastasis. In light of previous reports, we chose Colo205 cells for the following examination, as Colo205 cells have been reported to carry no T*β*R mutations, and Ls174T cells that express high CA19-9 carry mutant T*β*R ([@bib11]; [@bib33]). Furthermore, Colo205 cells express high levels of FUT3/6 and they secrete CA19-9 and sLe^x^ ([Supplementary Figure 1A--C](#sup1){ref-type="supplementary-material"}). We first examined the protein expression level of FUT3 and FUT6 upon TGF-*β* stimulation in cells transfected with random siRNA, siRNA for FUT3 (siFUT3), and/or siRNA for FUT6 (siFUT6) ([Figure 1A and B](#fig1){ref-type="fig"}; [Supplementary Figure 2](#sup1){ref-type="supplementary-material"}), and found that the expression level of FUT3 or FUT6 was not changed by TGF-*β* stimulation even in the presence or absence of siRNA. Although, as shown in [Figure 1C](#fig1){ref-type="fig"}, activation of Smad2 was suppressed in cells transfected with siFUT3 or siFUT6 but not in random siRNA-transfected cells. In the presence of both siFUT3 and siFUT6, phosphorylation of Smad2 was further inhibited upon TGF-*β* stimulation ([Figure 1C](#fig1){ref-type="fig"}). When other FUTs were suppressed by each siRNA, Smad2 phosphorylation status was not affected upon TGF-*β* stimulation, indicating that FUT3 and/or FUT6 were required for TGF-*β* signalling in CRC cell lines ([Supplementary Figure 3](#sup1){ref-type="supplementary-material"}).

Suppression of FUT3 and FUT6 resulted in inhibition of wound healing and cell invasion
--------------------------------------------------------------------------------------

In order to investigate the effect of FUT3 and/or FUT6 on cell invasion and migration, we performed wound healing and invasion assays. With regard to FUT3 and FUT6 expressions, we chose two cell lines that expressed high and low levels of FUT3/6 regardless of T*β*R status ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). In cells that express high levels of FUT3/6, CA19-9 and sLe^x^ were also highly expressed, but this was not the case in the cells expressing low levels of FUT3/6 ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). As shown in [Figure 2A](#fig2){ref-type="fig"}, the migration area of parental (non-treated, NT) or random siRNA transfected-Ls174T cells, which expressed high levels of FUT3/6, was decreased from 1.5±0.15 mm^2^ to 0.6±0.15 mm^2^ in NT and from 1.3±0.08 mm^2^ to 0.65±0.17 mm^2^ in random siRNA after 2 days, respectively. In contrast, the migration area of cells transfected with siRNA for FUT3 and/or FUT6 (siFUT3 0.45 mm^2^ reduction, siFUT6 0.4 mm^2^ reduction and siFUT3+6 0.23 mm^2^ reduction) was significantly lower compared with NT or random siRNA-transfected-cells. However, in cells expressing low levels of FUT3/6 (HCT15 cells), suppression of cell migration induced by siRNA transfection for FUT3 and/or FUT6 was not observed ([Figure 2](#fig2){ref-type="fig"}). Furthermore, the invasion assay revealed that the number of invaded cells was inhibited by siFUT3 and/or siFUT6 in Ls174T cells but not in HCT15 cells ([Figure 2B](#fig2){ref-type="fig"}), suggesting that FUT3 and/or FUT6 have an important role in cell migration and invasion in CA19-9-producing cells.

Inhibition of TGF-*β*-induced EMT in CRC cells by FUT3 and/or FUT6 siRNA
------------------------------------------------------------------------

We next examined whether EMT of CRC cells induced by TGF-*β* stimulation could be affected by siRNA for FUT3 and/or FUT6 using Colo205 and LS180 cells, which have been reported to carry no T*β*R mutations. The expression of E-cadherin and the number of epithelial cells were reduced in parental and random siRNA-transfected cells upon TGF-*β* stimulation ([Figure 3A--C](#fig3){ref-type="fig"}). In contrast, zinc finger E-box binding (ZEB) transcription factor ZEB1 and snail expression were induced upon TFG-*β* stimulation in random siRNA-transfected cells but not in siFUT3- and/or siFUT6-transfected cells. However, these effects were not observed in cells transfected with siFUT3 and/or siFUT6, indicating that both FUT3 and/or FUT6 are required for TGF-*β*-induced cell signalling and EMT. These observations were confirmed in three independent experiments.

We performed a protein array analysis to identify molecules related to cancer cell metastasis that were downregulated by siFUT3 or siFUT6 using protein array (data not shown). In Colo205 cells transfected with siRNA for FUT3 or FUT6, phosphorylation of HSP27 and p38delta was found to be downregulated compared with mock-transfected cells (data not shown). Hsp27 and p38delta have been reported to have important roles in cancer metastasis ([@bib9]; [@bib45]; [@bib39]; [@bib40]; [@bib53]; [@bib21]). We verified the phosphorylation status of Hsp27 and p38delta using serum-starved cell lysates. As shown in [Figure 4A](#fig4){ref-type="fig"}, siRNA for FUT3 and/or FUT6 suppressed phosphorylation of both molecules, but phosphorylation was not affected in random siRNA-transfected or parental cells upon TGF-*β* stimulation, suggesting that FUT3 and/or FUT6 are required for HSP27 and p38delta activation in TGF-*β* signalling.

Downregulation of T*β*R fucosylation by FUT3 and/or FUT6 siRNA
--------------------------------------------------------------

We next investigated the requirement for FUT3 and/or FUT6 in T*β*R fucosylation using lectin blot analysis. In a preliminary experiment, we found that TGF-*β* stimulation itself did not affect fucosylation of T*β*R ([Supplementary Figure 4](#sup1){ref-type="supplementary-material"}). However, siFUT3 and/or siFUT6 decreased the fucosylation status of type I T*β*R (T*β*R-I) by 50% compared with NT or random siRNA treatment. In contrast, the fucosylation status of type II T*β*R (T*β*R-II) was inhibited to a lesser extent by siFUT3 and/or siFUT6, indicating that activation of Smads and downstream signalling were dependent on fucosylation of T*β*R-I and minimally on T*β*R-II in CRC cell lines ([Figure 4B and C](#fig4){ref-type="fig"}). Furthermore, when fucosylated-T*β*Rs were detected by CA19-9 or sLe^x^ directly by each of the specific antibodies, reduction of each expression was observed ([Supplementary Figure 5](#sup1){ref-type="supplementary-material"}), indicating that T*β*R-bound CA19-9 and sLe^x^ might exist and regulate its signal transduction pathway directly. But further study should be required for future work.

The results of the study indicated that colorectal adenocarcinoma cells actively take up L-fucose, which accelerates their metastatic potential, and produce CA19-9. Therefore, L-fucose-bound nanoparticles, which we previously developed, might be suitable as a new therapeutic strategy, especially for treating patients with CRC expressing FUT3 or FUT6 ([@bib50]).

Discussion
==========

The present study demonstrates that FUT3 and FUT6 activate TGF-*β* signalling through fucosylation of T*β*R-I in CA19-9 and/or sLe^x^-producing CRC cells, leading to augmentation of their malignant potential.

It has been shown that enhanced activity of FUT3/6 induces sLe^a^ (CA19-9) and sLe^x^ expression, respectively, and potentiates the malignant potential of metastatic CRC ([@bib14]). These glycans induced by FUT promote extravasation of cancer cells via interacting with E-selectin on endothelial cells ([@bib48]; [@bib10]; [@bib15]; [@bib14]), but the molecular mechanisms remain unclear. In this study, we revealed that activation of HSP27 and p38, which mediate cell motility and migration, was downregulated by inhibition of T*β*R-I fucosylation induced by siFUT3 and siFUT6, resulting in the suppression of EMT.

Transforming growth factor-*β* has an important role in EMT by combining both Smad- and non-Smad-dependent signalling pathways ([@bib17]). In Smad-dependent signalling, Smads and Snail (EMT transcription factor) bind to regulatory promoter sequences of the gene encoding E-cadherin, leading to TGF-*β*-induced suppression of its expression ([@bib44]). Thus, the inhibition of E-cadherin expression induced by siFUT3/6 is considered to be mediated by the inactivation of the Smad pathway.

In relation to the Smad-independent pathway, p38 has been reported to have an important role in TGF-*β*-induced EMT ([@bib51]; [@bib18]; [@bib27]). Although the downstream pathway of p38 in TGF-*β*-induced EMT is not fully understood, previous reports have indicated that a relationship exists between p38 and HSP27 ([@bib9]; [@bib45]). Our results suggest that inhibition of FUT3 and FUT6 resulted in downregulation of HSP27 phosphorylation, possibly through inactivation of p38 induced by the suppression of TGF-*β* signalling. The expression of p38 in patients with cholangeal cell carcinoma has been shown to be correlated with sensitivity to chemotherapeutic agents as well as disease prognosis ([@bib40]). Furthermore, it has also been reported that HSP27 is associated with the metastatic potential of cancer cells ([@bib53]). These findings indicate that p38 and HSP27 are key molecules for cancer cell migration and metastasis in TGF-*β* signalling.

It has been demonstrated that FUT8 catalyses the transfer of a fucosyl moiety from GDP-fucose to the innermost GlcNAc residue of hybrid and complex N-linked oligosaccharides in glycoproteins via *α*(1,6)-linkage to form core-fucosylation. Knockdown of *FUT8* by siRNA has been shown to inhibit EMT by suppressing the TGF-*β* signalling pathway due to inhibition of core-fucosylation of TGF*β*-RII in renal tubular cells ([@bib23]). Furthermore, in FUT8-knockout mice, the growth of mouse embryonic fibroblasts was suppressed by inhibition of EGF receptor activation because of downregulation of core-fucosylation of the receptor ([@bib46]). Whereas, FUT3 or FUT6 adds α-1,3/1,4-fucose to GlcNAc residues in type 1 and type 2 precursors ([@bib4]). Our results obtained from CRC cells, based on lectin blot analysis, indicated that FUT3 and FUT6 regulate TGF*β*-Rs via glycosylation sites aside from the core-fucosylation induced by FUT8. Nevertheless, further investigation will be necessary to clarify the sites within T*β*Rs that are fucosylated by FUT3 and FUT6, and the mechanism of crosstalk in growth factor signalling induced by other FUTs such as FUT1, 8.

Overexpression of FUT3 and FUT6 might be predictive of a poor prognosis in patients with CRC not only because of the increased interaction between E-selectin and endothelial cells through sLe^a^/sLe^x^ but also via activation of TGF-*β* signalling through EMT, leading to enhanced metastatic potential. It should be noted that EGF/bFGF signalling augments EMT by inducing sLe^a^/sLe^x^ expression ([@bib38]). In our preliminary examination, we observed that 80% of stage IV patients were positive for both FUT3 and FUT6 expressions (data not shown), although we could not show a significant correlation between the metastatic stage and FUT3/6 expression due to the small size of the study. Future investigation may be necessary to reliably determine whether such a correlation exists.

We previously demonstrated that L-fucose-mediated cell targeting is a promising new therapeutic strategy for CA19-9-producing pancreatic adenocarcinoma ([@bib50]). Thus, fucose-targeting therapy could be effective for increasing survival in patients with metastatic CRC.
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![**Suppression of FUT3 and FUT6 inhibits Smad2 phosphorylation upon TGF-*β* stimulation.** (**A** and **B**) Western blot analysis for FUT3 (**A**) and FUT6 (**B**). Lysate from Colo205 cells transfected with indicated siRNAs was electrophoresed and immunoblotted with FUT3 and FUT6 antibodies. The same membranes were reprobed with *β*-actin to verify equal amounts of protein. (**C**) FUT3 and FUT6 were required for phosphorylation of Smad2. Colo205 cells transfected with random, siRNA for FUT3 (siFUT3), siRNA for FUT6 (siFUT6) or siRNA for FUT3 and 6 (siFUT3+6) were treated with TGF-*β* for 6 h, then probed with pSmad2. Western blots for *β*-actin and Smad2 represent equally loaded amounts of protein. The experiments were repeated three times to confirm the results.](bjc2013699f1){#fig1}

![**Suppression of either FUT3 and/or FUT6 by siRNA resulted in inhibition of cell migration and cell invasion.** (**A**) Wound healing assay for CRC cell lines transfected with siFUT3 and/or siFUT6. Representative photographs for the indicated conditions (upper panel). Wound field surface area was calculated according to the manufacturer\'s instructions. Lower panel shows the average wound field surface area based on randomly chosen wells. \**P*\<0.05 (NT or random vs. FUT3, FUT6, FUT3+6). (**B**) Cell invasion assay for CRC cell lines transfected with siFUT3 and/or siFUT6. Left panel shows representative photographs for the indicated conditions. Right panel shows the number of invaded cells that were transfected with the indicated siRNA. These results were confirmed by 3 independent experiments. \**P*\<0.05 (NT or random *vs* FUT3, FUT6, FUT3+6).](bjc2013699f2){#fig2}

![**Suppression of FUT3 and/or FUT6 inhibits TGF-*β*-induced EMT.** (**A** and **B**) Suppression of EMT by siFUT3 and/or siFUT6. Colo205 (**A**) and LS180 (**B**) cells were treated with TGF-*β* for 3 days after transduction with random siRNA, siFUT3 and/or siFUT6, then probed with Zeb1, Snail and E-cadherin. Western blot for *β*-actin was used to control for equal protein loading. The relative mean density is presented as the ratio to no treatment (NT). (**C**) Representative images of Colo205 cells and immunohistochemical staining for E-cadherin with or without TGF-*β*. Cells were treated with TGF-*β* for 3 days after transduction with random siRNA, siFUT3, and/or siFUT6, then probed with E-cadherin and visualised by TRITC. The expression of E-cadherin was quantified and presented as the ratio to no treatment (right panel). The results were confirmed by three independent experiments.](bjc2013699f3){#fig3}

![**Introduction of siFUT3 and/or siFUT6 resulted in inhibition of HSP27 and p38 activation through suppression of T*β*R-I fucosylation.** (**A**) Phosphorylation of HSP27 and p38 was inhibited by downregulation of FUT3 and/or FUT6. Colo205 cells transfected with random, siFUT3, siFUT6 or siFUT3+6 were treated with TGF-*β* under the conditions described in the text, harvested and used for western blotting. (**B** and **C**) Colo205 cells transfected with random, siFUT3, siFUT6 or siFUT3+siFUT6 were solubilised and immunoprecipitated with T*β*R-I (**B**) and T*β*R-II (**C**) antibodies. T*β*R-I and T*β*R-II-bound proteins were probed with biotinylated-AAL. The relative mean density is presented as the ratio to no treatment (NT). The results were confirmed by three independent experiments.](bjc2013699f4){#fig4}
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